We don't yet have the technology to develop a treatment for Alzheimer's disease, says Andreessen Horowitz general partner Jorge Conde.
"One of the things we look for when we make investments, we talked earlier about binary risk, is when developing a new therapeutic, you have to understand what the disease is doing," he said. "You have to understand what you need in it to affect the disease process, and then you have to have the capability to actually make that molecule or that cell or that gene."
Gluten Products could be banned. Food technology.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: